Our U19 program is focused on the pathophysiology and development of novel therapies for B. anthracis infection and sepsis. The Animal Core will serve as an integral component of the U19 program, providing support to all four Projects using a clinically relevant animal model of sepsis. The investigators will have a unique opportunity to answer critical questions by combining a genetically diverse, clinically relevant animal model, which has a proven history of mimicking human responses to sepsis with novel technologies being developed within our program. The Animal Core combines a unique set of facilities, management and technical expertise needed to achieve the Specific Aims of this program, as well as expert veterinary care, specialized reagent tools and strong expertise in advanced microscopy analysis of tissue samples. The personnel involved in the Core have more than three decades of experience in factious disease modeling in non-human primates. Optimal utilization of clinically relevant animal models for research on bioterrorism related pathogens such as B. anthracis requires a facility where animals are housed in appropriate biocontainment, research personnel are experienced in the methodologies required for infectious disease research, and development of novel therapeutics is required. Our Animal Core provides state-of-the-art facilities to develop animal models for studying disease pathogenesis and testing the efficacy and safety of novel therapeutics. Our facilities fully support biohazard research at ABSL-2 and meet all the NIH/CDC guidelines. Hence, this Core is a critical component in support of the proposals aimed at developing innovative therapeutics against B. anthracis, which we believe will be relevant to other Gram-positive pathogens.
The risk of anthrax infection is a serious problem for the military and high-risk civilians because of the high probability of malicious attacks with the spores that cause infection. This Core will support research projects aimed at understanding how pulmonary anthrax infection develops and progresses and developing novel therapeutics. Our state-of-the-art animal facility and our experienced staff will provide valuable veterinary and research support to the U19 investigators.
|Morris, D L; Fernando, M M A; Taylor, K E et al. (2014) MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun 15:210-7|
|Garman, Lori; Smith, Kenneth; Farris, A Darise et al. (2014) Protective antigen-specific memory B cells persist years after anthrax vaccination and correlate with humoral immunity. Toxins (Basel) 6:2424-31|
|Garman, Lori; Vineyard, Amanda J; Crowe, Sherry R et al. (2014) Humoral responses to independent vaccinations are correlated in healthy boosted adults. Vaccine 32:5624-31|
|Lupu, Florea; Keshari, Ravi S; Lambris, John D et al. (2014) Crosstalk between the coagulation and complement systems in sepsis. Thromb Res 133 Suppl 1:S28-31|
|Joshi, Sunil K; Lang, Mark L (2013) Fine tuning a well-oiled machine: Influence of NK1.1 and NKG2D on NKT cell development and function. Int Immunopharmacol 17:260-6|
|Lee, Benjamin C; Mayer, Chad L; Leibowitz, Caitlin S et al. (2013) Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy. Blood 122:803-6|
|Dumas, Eric K; Nguyen, Melissa L; Cox, Philip M et al. (2013) Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization. Vaccine 31:1856-63|
|Sun, Dawei; Popescu, Narcis I; Raisley, Brent et al. (2013) Bacillus anthracis peptidoglycan activates human platelets through FcýýRII and complement. Blood 122:571-9|
|Chiu, Christopher; Wrammert, Jens; Li, Gui-Mei et al. (2013) Cross-reactive humoral responses to influenza and their implications for a universal vaccine. Ann N Y Acad Sci 1283:13-21|
|Smith, Kenneth; Muther, Jennifer J; Duke, Angie L et al. (2013) Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovaxýý23 are serotype specific and facilitate opsonophagocytosis. Immunobiology 218:745-54|
Showing the most recent 10 out of 75 publications